Table 2.
Multivariate analysis for prognostic significance of clinicopathologic factors and tumor LINE-1 methylation in metastatic CRC
| Variables | Hazard ratio | (95% CI) | p-value |
|---|---|---|---|
| Female | 0.85 | (0.38–1.91) | 0.70 |
| Older patientsa | 0.63 | (0.28–1.41) | 0.26 |
| Rectum (vs. colon) | 0.84 | (0.38–1.85) | 0.66 |
| Well differentiation (vs. others) | 0.95 | (0.26–3.41) | 0.94 |
| Recurrence (vs. stage IV) | 0.81 | (0.31–2.14) | 0.67 |
| Multiple organs (vs. one organ) metastasis | 0.85 | (0.34–2.08) | 0.72 |
| Previous treatment with 5-FU | 1.62 | (0.55–4.77) | 0.38 |
| Second line (vs. first line) chemotherapy | 1.08 | (0.37–3.11) | 0.89 |
| LINE-1 hypomethylation b | 2.74 | (1.19–6.29) | 0.018 |
aAge: older (>65 y) versus younger (65 y ≥) patients
bThe levels of tumor LINE-1 methylation were classified as hypomethylation versus hypermethylation based on the cutoff value (51.7%) determined by the ROC curve (Fig. 3a)